The gift will create the John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory at Houston Methodist. Photo via houstonmethodist.org

Houston Methodist announced that it has received a $10 million gift from the The John M. O’Quinn Foundation to support research into neurological disorders, including Alzheimer’s disease, Parkinson’s disease and others.

The gift will create the John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory at Houston Methodist, which will be led by Dr. Jun Li, who chairs the department of neurology at the Houston Methodist Neurological Institute. The NIH-backed researcher and his team will provide care, clinical trial opportunities and subspecialty programs through the lab, according to a release from Houston Methodist.

The funds will also be used to recruit neurodegenerative disorders specialists to lab by creating endowed research chairs, research fellowships and funding for pilot studies.

"Many neurodegenerative diseases are chronic and significantly impact the quality of life, causing pain, weakness, loss of ambulation and sensory loss,” Li says in a statement. “Our team is committed to working with patients to help make their lives better through treatment, and this generous gift fuels our determination to do even more and to help find therapies for these neurological diseases. This commitment from The John M. O’Quinn Foundation will support an interdisciplinary team of neurologists and neuroscientists to further explore treatment options.”

The O'Quinn Foundation has been a long-time supporter of the hospital group, according to Houston Methodist, and has had members of its organization suffer from neurodegenerative disorders.

"As our population continues to live longer, we believe it’s critical to help now, and we know Houston Methodist is best positioned with its renowned researchers and clinicians like Dr. Li to help those with neurodegenerative diseases to have a better quality of life, and ultimately, a treatment for these diseases that impact so many,” President and Executive Director of the foundation Robert C. Wilson III says in the statement.

Earlier this year, Houston Methodist also received a $1 million grant from Susan and William “Dub” Henning, Jr. to support Alzheimer’s research at the Nantz National Alzheimer Center at the hospital. It created the Susan and William Henning Jr. Neurodegenerative Research Endowment.

Meanwhile, over the summer, a Houston clinical-stage biotech that treats neurodegenerative diseases company went public. The company, Coya Therapeutics (Nasdaq: COYA), has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again and closed a $15.25 million IPO in January. Click here to learn more about the company's treatments for ALS and Alzheimer's.

Houston Methodist's Nantz National Alzheimer Center received a $1 million donation to continue research in neurodegenerative diseases. Photo via Houston Methodist

Houston hospital snags $1M to advance Alzheimer’s research

money moves

Thanks to a recent donation, Houston Methodist is setting up an endowment to support research in neurodegenerative diseases.

Susan and William “Dub” Henning, Jr. have committed to a $1 million gift to Houston Methodist to support Alzheimer’s research at the Nantz National Alzheimer Center at the hospital. This gift will be used to create the Susan and William Henning Jr. Neurodegenerative Research Endowment and in response, a NNAC family room will be named in memory of Dub’s parents, Lena and William Henning.

“Knowing the impact that Alzheimer’s can have not only on patients, but also on the immediate and extended family members experiencing the disease inspired us to support the work being done at the Nantz National Alzheimer Center,” says Dub Henning in a news release. “We want to give hope to families struggling with this disease and contribute to ultimately finding a cure.”

Every year, the NNAC — led by Joseph C. Masdeu — treats thousands of patients looking to prevent Alzheimer’s disease, slow memory loss progression, and improve their quality of life. In 2021 alone, the center provided more than 4,000 patient visits. The fresh funding will allow for Dr. Masdeu's research projects — including more than 26 current studies, 14 in clinical trials and 12 studies to clarify the nature of diseases causing dementia — to continue the important work.

“One of our clinical trials will determine the effects of exercise in preventing deposits of amyloid and tau, two of the proteins that accumulate in the brain of people living with Alzheimer’s disease, and we’re also exploring the role of proper sleep in disease development,” says Masdeu in the release. “Among other studies, we are collaborating with Baylor College of Medicine to define genetic and chemical factors predisposing to the accumulation of amyloid and tau in the brain of people at all stages of the Alzheimer’s spectrum.

"These promising developments would not be possible without the compassion and generosity of community supporters like the Henning family," he continues.

Susan and William “Dub” Henning, Jr. gave a $1 million gift to Houston Methodist. Photo courtesy of Houston Methodist

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

XSpace plans $250M industrial condo expansion with RAFA Racing Club

growth mode

Houston-based XSpace Group has teamed up with two other Houston companies, RAFA Racing Club and Maximo Capital, to develop five industrial condo projects that pair flex space and high-end car storage space with a members-only clubhouse for motorsports enthusiasts.

The five projects will be built in the Dallas-Fort Worth; Miami-Boca Raton; Charlotte-Mooresville, North Carolina; Phoenix-Scottsdale; and Los Angeles markets. Other markets, including Las Vegas, are under consideration for future phases.

XSpace says the initial five-project venture will generate estimated sales of $250 million. Condos will be available to rent or own.

The ground floor of each project will feature a RAFA Racing Club Social & Performance Centre, a members-only clubhouse, event space and lifestyle hub. The remaining floors will offer space for car storage, collectibles, offices and studios. RAFA will operate the ground floor of each building.

“Our goal from day one with RAFA Racing has been to connect people through a shared love of performance and community,” Rafael Martinez, founder of RAFA Racing Club and principal of Maximo Capital, said in a news release. “By pairing XSpace’s forward-thinking condominium design with the exclusive hospitality, networking and high-performance environment of a RAFA Racing Club clubhouse, we’re establishing a community blueprint where passion meets community.”

Each clubhouse will offer:

  • Lounges
  • Dining, working and networking spaces
  • Concierge service
  • Driving simulators
  • Fitness and conditioning capabilities

“We’re building the most valuable community-driven real estate product in America — and RAFA Racing Club is the anchor that makes it unlike anything else on the market," Byron Smith, founder of XSpace, added in a release. “By integrating our flexible, high-end industrial condominiums with RAFA’s world-class hospitality and automotive community spaces, we are completely redefining what commercial real estate can be for the motorsports enthusiast.”

RAFA operates facilities for motorsports fans in Houston and Austin. The clubs, geared toward wealthy people, entrepreneurs, executives, and brand partners, combine a clubhouse, garage, paddock (racing’s version of a locker room), a “human performance” center and driver training programs.

RAFA plans to open seven clubs in the U.S. and three outside the U.S. over the next four years.

XSpace operates a high-end office, warehouse, and lifestyle condo project in Austin and is building a project in Houston that’s set to open in 2027.

Walmart expands drone delivery service to 8 new Houston-area stores

Now Landing

More Walmart delivery drones are now buzzing around Houston-area skies.

In January, Walmart launched its drone delivery service in partnership with Wing at five locations in the Houston area. The retail giant just added eight more stores to its Houston-area drone delivery network.

Wing says the expansion makes drone delivery available to more than 1 million residents of the Houston area. “Many can now bypass notorious Houston traffic to get everyday Walmart essentials delivered by drone in minutes,” Wing said in a release.

The eight Walmart stores that joined the drone delivery network are:

  • 13003 Tomball Pkwy. Houston
  • 12353 FM 1960 Rd. West, Houston
  • 2901 Riley Fuzzel Rd., Spring
  • 20310 U.S. Highway 59, New Caney
  • 1025 Sawdust Rd., Spring, TX 77380
  • 13484 Northwest Fwy., Houston, TX
  • 13750 East Fwy., Houston
  • 3506 Highway 6 South, Houston

Stores where drone delivery was already available are:

  • 14215 FM 2100 Rd., Crosby
  • 1313 N. Fry Rd., Katy
  • 15955 FM 529 Rd., Houston
  • 255 FM 518, Kemah
  • 6060 N. Fry Rd., Katy

Houstonians can learn whether their address is eligible for drone delivery from a Walmart store by visiting wing.com/walmart. Drone-delivered orders can be placed on the Walmart app, the Wing app, or at Walmart.com.

Once an order is ready, it’s loaded onto a delivery drone. The drone then flies up to 60 mph and at a cruising altitude of about 150 feet to reach the customer’s home. The average flight takes less than 5 minutes.

Once it arrives at the customer’s home, the drone stops, hovers at roughly 23 feet, and lowers the order via a tether. Wing says its drones gently lower orders to the ground to protect fragile items like eggs and coffee.

---

This article originally appeared on CultureMap.com.

TMC expands Korea BioBridge, welcomes 12 biotech companies to Houston

welcome to hou

The powerful partnership between Texas Medical Center (TMC) innovation and the world of Korean biotech advancement is already growing in scope. Just six months after the new TMC Republic of Korea BioBridge was first announced, 12 new companies from the Republic of Korea will establish on-site presences in Houston to further collaboration between the two nations and medical industries.

The expansion comes from a new agreement between TMC and the Korea Health Industry Development Institute (KHIDI). William McKeon, president and CEO of Texas Medical Center, applauded the move and predicted it would benefit both Houston and Korea immensely.

“Korea has established itself as a global leader in biohealth innovation, with a growing pipeline of breakthrough technologies across digital health, biotechnology, and medical devices,” McKeon said in the news release. “Through the TMC Korea BioBridge, we are creating a direct connection between Korea’s innovators and the world’s largest medical city. This collaboration between TMC and KHIDI provides companies with a place to establish a presence, build strategic relationships, engage with leading clinicians and researchers, and accelerate the path toward commercialization and patient impact in the United States.”

The companies that will be in residence at the TMC Innovation Factory include Ardens Lifescience, whose new CAROL device is currently in human trials tackling lung cancer by using the airway network as electrodes to perform bronchoscopic ablation; stem cell-based gene therapy firm CELLeBRAIN, currently working on neurological disorders and solid cancers; and Wellysis, the developer of the S-Patch wearable cardiac monitoring device.

Additional companies include:

  • Antigravity
  • ARPI
  • CTCELLS
  • elecell
  • HUVER Inc.
  • Hutom
  • ORGANOIDSCIENCES
  • YOUTH BIO GLOBAL
  • Seoul Medical Informatics Intelligence Lab Inc.

“This collaboration establishes a strong foundation for connecting Korea’s biohealth innovation ecosystem with world-class clinical and innovation resources in the United States,” Younghun Jeong, executive director of the KHIDI, added in the news release. “Through partnerships with Texas Medical Center and the Korean-American Medical Association Texas, we look forward to fostering meaningful collaboration among innovators, clinicians, and industry leaders while creating new opportunities for clinical validation, commercialization, and global growth. KHIDI remains committed to expanding global partnerships that support biohealth innovation, clinical collaboration, commercialization, and international growth.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.